Bimekizumab for Ankylosing Spondylitis (BE AGILE 2 Trial)

Phase 2

Waitlist Available

Research Sponsored by UCB Biopharma SRL

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline of as0008, week 48 (as0009)

Awards & highlights

No Placebo-Only Group

Summary

This trial is studying the safety and tolerability of bimekizumab in people with ankylosing spondylitis. Bimekizumab helps reduce inflammation and pain by blocking proteins that cause these symptoms. It has shown promise in early studies for treating psoriatic disease and ankylosing spondylitis.

Eligible Conditions

Ankylosing Spondylitis

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline of as0008, week 48 (as0009)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline of as0008, week 48 (as0009)

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline of as0008, week 48 (as0009) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Percentage of Participants With Serious Adverse Event (SAE) During the Study

Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study

Secondary study objectives

Change From Baseline of AS0008 in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Total Score to Week 48

Percentage of Participants Who Withdrew Due to an Treatment-emergent Adverse Event (TEAE) During the Study

Percentage of Participants With Axial Spondyloarthritis International Society 20% Response Criteria (ASAS20) at Week 48 Calculated Relative to Baseline of AS0008

+1 more